Rohit Bhatia, Mv Padma Srivastava, Saman Fatima, Risha Sarkar, Imnameren Longkumer, Shailesh Gaikwad, Leve S Joseph Devaranjan, Ajay Garg, Jeyaraj Durai Pandian, Dheeraj Khurana, P N Sylaja, Shweta Jain, Deepti Arora, Aneesh Dhasan, Sanjith Aaron, Angel T Miraclin, Pamidimukkala Vijaya, Srijithesh P Rajendran, Jayanta Roy, Biman Kanti Ray, Vivek Nambiar, Paul J Alapatt, Meenakshi Sharma
RATIONALE: Rapid and timely treatment with intravenous thrombolysis and endovascular treatment (EVT) in patients with acute ischaemic stroke (AIS) and large vessel occlusion (LVO) significantly improves patient outcomes. Bridging therapy is the current standard of care in these patients. However, an incompletely answered question is whether one thrombolytic agent is better than another during bridging therapy. AIM: The current study aims to understand if one thrombolytic agent is superior to the other during bridging therapy in the treatment of AIS and LVO...
2024: BMJ neurology open